Walleye Capital’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Walleye Capital’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-172,459	Closed	-$1.66M	–	5378
2024 Q4	$1.66M	Buy	+172,459	New	+$900K	﹤0.01%	1958
2023 Q1	–	Sell	-64,371	Closed	-$341K	–	4462
2022 Q4	$341K	Buy	+64,371	New	+$294K	0.01%	1703

Other funds holding PSTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Walleye Capital's PSTX Position: Q1 2025 in Review

Walleye Capital sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 172,459 shares — an estimated $1.66M sold.

Walleye Capital first reported a position in PSTX in Q4 2022 and held it in 2 quarters. The position peaked at $1.66M in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

Walleye Capital reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Walleye Capital sold 172,459 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $1.66M.
Walleye Capital first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Walleye Capital's Poseida Therapeutics, Inc. Common Stock position peaked at $1.66M in Q4 2024.
1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Walleye Capital's 13F filing for Q1 2025, filed 14 May 2025.